Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secretagogue effect of PDE4 inhibitor apremilast on human salivary gland organoids obtained from primary Sjögren's syndrome patients.
Manfrè V, Parisi S, Caligiuri I, Repetto O, Zabotti A, Pegolo E, Fabro C, De Vita S, Canzonieri V, Di Loreto C, Rizzolio F, Quartuccio L. Manfrè V, et al. Among authors: de vita s. Clin Exp Rheumatol. 2023 Dec;41(12):2493-2501. doi: 10.55563/clinexprheumatol/7f4fzu. Epub 2023 Dec 23. Clin Exp Rheumatol. 2023. PMID: 38149513 Free article.
Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review.
Jousse-Joulin S, Milic V, Jonsson MV, Plagou A, Theander E, Luciano N, Rachele P, Baldini C, Bootsma H, Vissink A, Hocevar A, De Vita S, Tzioufas AG, Alavi Z, Bowman SJ, Devauchelle-Pensec V; US-pSS Study Group. Jousse-Joulin S, et al. Among authors: de vita s. Rheumatology (Oxford). 2016 May;55(5):789-800. doi: 10.1093/rheumatology/kev385. Epub 2015 Dec 14. Rheumatology (Oxford). 2016. PMID: 26667216 Review.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: de vita s. Arthritis Rheumatol. 2024 Nov 18. doi: 10.1002/art.43059. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39557617
Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study.
Goules AV, Chatzis L, Pezoulas VC, Patsouras M, Mavragani C, Quartuccio L, Baldini C, De Vita S, Fotiadis DI, Tzioufas AG. Goules AV, et al. Among authors: de vita s. Lancet Rheumatol. 2024 Oct;6(10):e693-e702. doi: 10.1016/S2665-9913(24)00183-8. Epub 2024 Aug 22. Lancet Rheumatol. 2024. PMID: 39182505
Consensus-driven target product profiles for curative sickle cell disease gene therapies.
Bukini D, Makani J, McCune J, Lee D, Bansbach C, De Vita S, Kemps D, Amin E, Spector J, Tisdale J. Bukini D, et al. Among authors: de vita s. Mol Ther Methods Clin Dev. 2024 Jun 22;32(3):101287. doi: 10.1016/j.omtm.2024.101287. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39104574 Free PMC article. Review.
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.
Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, Baraliakos X, De Marco G, De Vita S, Errichetti E, Quartuccio L, Silvagni E, Smolen JS, Tinazzi I, Watad A, Schett G, McGonagle DG, Simon D. Zabotti A, et al. Among authors: de vita s. RMD Open. 2024 Apr 10;10(2):e004314. doi: 10.1136/rmdopen-2024-004314. RMD Open. 2024. PMID: 38599649 Free PMC article.
457 results